Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy

scientific article published on 17 June 2013

Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.CLML.2013.03.016
P698PubMed publication ID23787122
P5875ResearchGate publication ID240308573

P50authorSagar LonialQ66431075
Paul G. RichardsonQ87712102
P2093author name stringJonathan L Kaufman
Claire Fabre
P2860cites workLysine acetylation targets protein complexes and co-regulates major cellular functionsQ27860589
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectmultiple myelomaQ467635
P304page(s)370-376
P577publication date2013-06-17
P1433published inClinical Lymphoma, Myeloma & LeukemiaQ5133774
P1476titleHistone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy
P478volume13

Reverse relations

cites work (P2860)
Q38752460Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Q38989789Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
Q26747768Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
Q51772922Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Q36298507Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
Q36146330Histone Deacetylases in Bone Development and Skeletal Disorders.
Q38910971In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Q64099073Management of cardiovascular risk in patients with multiple myeloma
Q27015931Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells
Q38240941Not too little, not too much-just right! (Better ways to give high dose melphalan).
Q39234159Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Q39051716Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial
Q37687419Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells
Q33442923Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
Q38258197Recent advances and future directions in targeting the secretory apparatus in multiple myeloma
Q38928346Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin A on the energy metabolism of breast cancer cells
Q37199772Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
Q39379624Role of epigenetics-microRNA axis in drug resistance of multiple myeloma
Q39041783Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
Q28075599The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis
Q38400460The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Q64059633The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
Q38815402Treatment of MM: Upcoming Novel Therapies
Q38476564miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.

Search more.